Literature DB >> 15086318

The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization.

M Laffan1, S A Brown, P W Collins, A M Cumming, F G H Hill, D Keeling, I R Peake, K J Pasi.   

Abstract

von Willebrand disease (VWD) is the commonest inherited bleeding disorder. However, despite an increasing understanding of the pathophysiology of VWD, the diagnosis of VWD is frequently difficult because of uncertainty regarding the relationship between laboratory assays and function in vivo. The objective of this guideline is to provide contemporary advice on a rational approach to the diagnosis of VWD. This is the second edition of this UK Haemophilia Centre Doctors' Organisation (UKHCDO) guideline and supersedes the previous edition which was published in 1997.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15086318     DOI: 10.1111/j.1365-2516.2004.00894.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  17 in total

1.  Recommendations for the transfusion management of patients in the peri-operative period. I. The pre-operative period.

Authors:  Giancarlo Maria Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2011-01       Impact factor: 3.443

Review 2.  Diagnostic approach to von Willebrand disease.

Authors:  Christopher Ng; David G Motto; Jorge Di Paola
Journal:  Blood       Date:  2015-02-23       Impact factor: 22.113

Review 3.  Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH.

Authors:  I Bodó; J Eikenboom; R Montgomery; J Patzke; R Schneppenheim; J Di Paola
Journal:  J Thromb Haemost       Date:  2015-05-09       Impact factor: 5.824

4.  Optimization of the automated, CS-2000i™ method for measuring low levels of von Willebrand factor ristocetin cofactor activity (VWF:RCo).

Authors:  Tomoko Matsumoto; Keiji Nogami; Masahiro Okuda; Midori Shima
Journal:  Int J Hematol       Date:  2014-12-06       Impact factor: 2.490

5.  Correlation between von Willebrand factor antigen, von Willebrand factor ristocetin cofactor activity and factor VIII activity in plasma.

Authors:  Giuseppe Lippi; Massimo Franchini; Gian Luca Salvagno; Martina Montagnana; Giovanni Poli; Gian Cesare Guidi
Journal:  J Thromb Thrombolysis       Date:  2007-09-03       Impact factor: 2.300

Review 6.  The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology.

Authors:  Mike A Laffan; Will Lester; James S O'Donnell; Andrew Will; Robert Campbell Tait; Anne Goodeve; Carolyn M Millar; David M Keeling
Journal:  Br J Haematol       Date:  2014-08-12       Impact factor: 6.998

7.  Bleeding disorders in the tribe: result of consanguineous in breeding.

Authors:  Munira Borhany; Zaen Pahore; Zeeshan Ul Qadr; Muhammad Rehan; Arshi Naz; Asif Khan; Saqib Ansari; Tasneem Farzana; Muhammad Nadeem; Syed Amir Raza; Tahir Shamsi
Journal:  Orphanet J Rare Dis       Date:  2010-09-07       Impact factor: 4.123

8.  The Prevalence of von Willebrand Disease and Significance of in Vitro Bleeding Time (PFA-100) in von Willebrand Disease Screening in the İzmir Region.

Authors:  Fatih Sap; Tülay Kavaklı; Kaan Kavaklı; Ceyhun Dizdarer
Journal:  Turk J Haematol       Date:  2013-03-05       Impact factor: 1.831

9.  The management of patients with congenital von Willebrand disease during surgery or other invasive procedures: focus on antihemophilic factor/von Willebrand factor complex.

Authors:  Massimo Franchini; Giuseppe Lippi
Journal:  Biologics       Date:  2007-09

10.  von Willebrand's disease: a report from a meeting in the Åland islands.

Authors:  E Berntorp; I Peake; U Budde; M Laffan; R Montgomery; J Windyga; A Goodeve; P Petrini; M von Depka; W Miesbach; D Lillicrap; A B Federici; R Lassila; G White
Journal:  Haemophilia       Date:  2012-09       Impact factor: 4.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.